Should we offer prenatal exome sequencing for intrauterine growth restriction or short long bones? A systematic review and meta-analysis

Fionnuala Mone*, Rhiannon Mellis, Heinz Gabriel, Caitlin Baptiste, Jessica Giordano, Ronald Wapner, Lyn S. Chitty

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)
96 Downloads (Pure)

Abstract

Objective
This study aimed to determine the incremental yield of prenatal exome sequencing over chromosomal microarray or G-banding karyotype in fetuses with: (1) intrauterine growth restriction related to placental insufficiency or (2) short long bones, in isolated and nonisolated instances for both scenarios.

Data Sources
Data were collected via electronic searches for relevant citations from January 2010 to April 10, 2022 in MEDLINE, Embase, Web of Science, and Cochrane, and using relevant bibliographies and data generated in-house.

Study Eligibility Criteria
Included were prospective or retrospective cohort studies and/or case series with: (1) n>5 cases of short long bones and/or intrauterine growth restriction undergoing prenatal sequencing with a clearly defined phenotype including assessment of placental function; (2) testing based on prenatal phenotype only; (3) a nondiagnostic chromosomal microarray/karyotype; and (4) known results of genetic testing.

Methods
Incremental yield was calculated for each study and as a pooled value for the aforementioned groups using a random-effects model. Results were displayed in forest plots with 95% confidence intervals. Heterogeneity was assessed statistically using Higgins’ I2. Publication bias was assessed graphically using funnel plots. Quality assessment was performed using modified Standards for Reporting of Diagnostic Accuracy criteria (International Prospective Register of Systematic Reviews registration number CRD42022324680).

Results
Nineteen studies were included (n=452 cases). The apparent incremental yields with prenatal sequencing were: (1) 4% (95% confidence interval, −5.0 to 12; I2=0%) in isolated intrauterine growth restriction with evidence of placental insufficiency, (2) 30% (95% confidence interval, 13–47; I2=1%) in intrauterine growth restriction with additional structural anomalies, (3) 48% (95% confidence interval, 26–70; I2=73%) in isolated short long bones, and (4) 68% (95% confidence interval, 58–77; I2=51%) in short long bones with additional skeletal anomalies. Of the 37 short long bone cases with a diagnosis, 32 had a skeletal dysplasia, with thanatophoric dysplasia and osteogenesis imperfecta being the most common (both 21.6% [n=8/37]). In fetuses with short long bones and additional skeletal features, osteogenesis imperfecta was the most common diagnosis (28% [n=57/204]). Where documented, the inheritance patterns were de novo in 75.4% (n=150) of cases.

Conclusion
Prenatal sequencing adds substantially to incremental yield over chromosomal microarray in fetuses with short long bones or multisystem intrauterine growth restriction. Robust studies are required to assess the utility of fetal sequencing in isolated intrauterine growth restriction with evidence of placental insufficiency, which cannot be recommended on the basis of current evidence.


Original languageEnglish
Pages (from-to)409-417.e4
Number of pages13
JournalAmerican Journal of Obstetrics and Gynecology
Volume228
Issue number4
Early online date29 Mar 2023
DOIs
Publication statusPublished - Apr 2023

Keywords

  • Fetal growth restriction
  • exome sequencing
  • Prenatal
  • next generation sequencing

Fingerprint

Dive into the research topics of 'Should we offer prenatal exome sequencing for intrauterine growth restriction or short long bones? A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this